Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urinary Biomarkers for Prostate Cancer.
Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. Giunchi F, et al. Among authors: massari f. Curr Drug Metab. 2017 Oct 16;18(8):723-726. doi: 10.2174/1389200218666170518161140. Curr Drug Metab. 2017. PMID: 28524004 Review.
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Santoni M, et al. Among authors: massari f. Cancer Immunol Immunother. 2013 Dec;62(12):1757-68. doi: 10.1007/s00262-013-1487-6. Epub 2013 Oct 17. Cancer Immunol Immunother. 2013. PMID: 24132754 Free PMC article. Review.
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Santoni M, et al. Among authors: massari f. Cancer Metastasis Rev. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. Cancer Metastasis Rev. 2014. PMID: 24337954 Review.
Adenocarcinoma of the paraurethral glands: a case report.
Massari F, Ciccarese C, Modena A, Maines F, Segala D, Luchini C, Marcolini L, Cavicchioli F, Cavalleri S, Bria E, Brunelli M, Martignoni G, Artibani W, Tortora G. Massari F, et al. Histol Histopathol. 2014 Oct;29(10):1295-303. doi: 10.14670/HH-29.1295. Epub 2014 Mar 7. Histol Histopathol. 2014. PMID: 24604416
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: massari f. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma.
Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Caliò A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. Massari F, et al. Pathology. 2014 Oct;46(6):523-6. doi: 10.1097/PAT.0000000000000150. Pathology. 2014. PMID: 25188333
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Santoni M, et al. Among authors: massari f. Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4. Ann Surg Oncol. 2015. PMID: 25472645
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors.
Fiorini C, Massari F, Pedron S, Sanavio S, Ciccarese C, Porcaro AB, Artibani W, Bertoldo F, Zampini C, Sava T, Ficial M, Caliò A, Chilosi M, D'Amuri A, Sanguedolce F, Tortora G, Scarpa A, Delahunt B, Porta C, Martignoni G, Brunelli M. Fiorini C, et al. Among authors: massari f. Am J Cancer Res. 2014 Nov 19;4(6):907-15. eCollection 2014. Am J Cancer Res. 2014. PMID: 25520878 Free PMC article.
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: massari f. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290
716 results